TPP1

Tripeptidyl-peptidase 1

394 patent compounds predicted against TPP1, 351 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL29358745	1.00	2/20
SCHEMBL29380618	1.00	2/20
SCHEMBL29931136	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL29688472	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL24532058	0.83	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL24532062	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20
SCHEMBL22025030	0.81	2/20

Germline variants in TPP1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full TPP1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to TPP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats	PHASE4	COMPLETED
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome	PHASE4	COMPLETED
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis	PHASE4	COMPLETED
The Effects of Neprilysin on Glucagon-like Peptide-1	PHASE4	COMPLETED
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)	PHASE4	COMPLETED
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Atazanavir and Endothelial Function in Older HIV Patients	PHASE2/PHASE3	COMPLETED
Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients	PHASE3	ENROLLING_BY_INVITATION
Sitagliptin and Endothelial Dysfunction	PHASE3	UNKNOWN
A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease	PHASE3	COMPLETED
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis	PHASE3	COMPLETED
Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis	PHASE2/PHASE3	COMPLETED
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease	PHASE1/PHASE2	COMPLETED
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease	PHASE1/PHASE2	RECRUITING
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency	PHASE2	COMPLETED
Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)	PHASE1	COMPLETED
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis	PHASE1	COMPLETED
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus	PHASE1	COMPLETED
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients	nan	ACTIVE_NOT_RECRUITING
Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis	nan	UNKNOWN
Genetic Analysis of Thyrotoxic Periodic Paralysis	nan	COMPLETED
DPP4 Activity, Microvascular Reactivity and Inflammation	nan	COMPLETED
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects	nan	UNKNOWN
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients	nan	COMPLETED
A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects	nan	COMPLETED
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease	nan	APPROVED_FOR_MARKETING

Related proteins — ESM-2 sequence neighbours (a TPP1 binder may also engage these)

Protein	Name	Similarity
Q60HH1	—	1.000	Q60HH1 →
O89023	—	1.000	O89023 →
Q5RFL1	—	1.000	Q5RFL1 →
Q9XSB8	—	1.000	Q9XSB8 →
Q5IS74	—	1.000	Q5IS74 →
Q9EQV6	—	0.999	Q9EQV6 →
Q0V8B6	—	0.995	Q0V8B6 →
P29121	—	0.977	P29121 →
O95479	—	0.973	O95479 →
O46432	—	0.973	O46432 →
Q9H4A9	—	0.971	Q9H4A9 →
Q8BNJ2	—	0.969	Q8BNJ2 →
F8W2M8	—	0.969	F8W2M8 →
A8T688	—	0.969	A8T688 →
A8T658	—	0.969	A8T658 →
A8T682	—	0.968	A8T682 →
Q6RHW4	—	0.968	Q6RHW4 →
Q9Z2Q3	—	0.968	Q9Z2Q3 →
Q61139	—	0.967	Q61139 →
Q12891	—	0.967	Q12891 →
ADAMTS4	A disintegrin and metalloproteinase with thrombospondin motifs 4	0.967	landscape →
O09159	—	0.967	O09159 →
Q9UQQ1	—	0.967	Q9UQQ1 →
Q76HN1	—	0.967	Q76HN1 →
A8T695	—	0.966	A8T695 →
P43477	—	0.966	P43477 →
PAOX	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase	0.966	landscape →
PLD3	5'-3' exonuclease PLD3	0.966	landscape →
Q5E985	—	0.965	Q5E985 →
Q9DA79	—	0.965	Q9DA79 →